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This is the fifth in a series of articles highlighting the delivery of
‘‘packages of care’’ for mental health disorders in low- and middle-
income countries. Packages of care are combinations of treatments aimed
at improving the recognition and management of conditions to achieve
optimal outcomes.
Introduction
Dementia is a chronic organic brain syndrome, characterised by
progressive impairment of multiple cortical functions, including
memory, learning, orientation, language, comprehension, and
judgement. Diagnosis requires decline in cognitive function and
independent living skills (Box 1) [1]. However, for carers and
people with dementia, the behavioural and psychological symp-
toms of dementia (BPSD) affect most quality of life, are an
important cause of carer strain [2], and a common reason for
institutionalisation [3]. Alzheimer’s disease, vascular dementia,
dementia with Lewy bodies, and frontotemporal dementia are the
most common dementia subtypes, but mixed pathologies may be
the norm [4]. Some rare causes (subdural haematoma, normal
pressure hydrocephalus, hypercalcaemia, and deficiencies of
thyroid hormone, vitamin B12, and folic acid) can be treated.
Otherwise, the progressive course of dementia cannot be altered,
but symptomatic treatments and support can be helpful.
Dementia mainly affects older people. Few cases start before the
age of 65 y, after which prevalence doubles with every5-y increase in
age [5]. Globally, 24.3 million people are affected by dementia and
4.6 million new cases occur annually [6]. The prevalence of dementia
is expected to double every 20 y, reaching 81.1 million by 2040, an
increase of 100% in developed countries and of more than 300% in
India, China, and their neighbours. Prevalence is lower in low- and
middle-income countries (LMICs) than in high income countries
(HICs) [6], perhaps because of underdetection of mild cases [7].
Nevertheless, most people with dementia live in LMICs—60% in
2001 rising to 71% by 2040 [6].
Dementia contributes 11.2% of years lived with disability among
people aged 60 y and over, a higher proportion than stroke (9.5%),
musculoskeletaldisorders (8.9%), cardiovascular disease(5.0%),and
cancer (2.4%) [8]. Its global cost is estimated to be US$317 billion,
77% of this total arising in HICs where formal sector care costs
increase with disease progression, and institutionalization is the
main cost driver [9]. Family care is more important in resource-
poor countries, accounting for 56% of costs in low-income
countries, 42% in middle-income countries, and 31% in HICs
[9]. In a pilot study in 26 LMIC centers, carers were economically
disadvantaged [10]. A fifth of carers had cut back on paid work, and
paid carerswerecommon, whichadded tothe economic strain[10].
Compensatory benefits were practically nonexistent [10,11].
In three qualitative studies in India, features of dementia were widely
recognized and named [12–14]. However, dementia was perceived as
normal ageing rather than as a medical condition. The consequences
were limited help seeking [13] despite disability and carer strain [15],
no structured training on the recognition and management of
dementia, and no constituency to advocate for more responsive care
services [14]. People with dementia were excluded from residential
care [13]. Carers misinterpreted BPSD as deliberate misbehavior [14].
BPSD can also lead to stigma and blame attaching to the carers [2]. In
India, likely causes of dementia were cited as ‘‘neglect by family
members, abuse, tension and lack of love’’ [13].
In this article, we focus on the effective management of dementia
in LMICs, reviewing the evidence on efficacy of interventions and
their delivery derived from LMICs where possible. Given the
paucity of relevant evidence from LMICs, we also cite systematic
reviews and meta-analyses based on trials from HICs. On the basis
of our review we propose a package of care—a combination of
treatments aimed at improving the recognition and management of
conditions to achieve optimal outcomes—for dementia.
The Evidence on the Management of Dementia
The principal goals of management of dementia are: early
diagnosis; optimization of physical health, cognition, activity, and
wellbeing; detection and treatment of BPSD; and the provision of
information and long-term support to carers. The evidence base for
dementia care comes, overwhelmingly, from HICs (Table 1).All the
studies discussed below refer to HICs, unless otherwise specified.
Detection and Diagnosis of Dementia
Many cases of dementia, particularly in LMICs, go undetected,in
part because of lack of awareness. Awareness of this disorder can be
boosted by dissemination of information from governments, health
care providers, and media. Help-seeking can be encouraged by
improved case-finding. In India and Brazil, for example, community
Citation: Prince MJ, Acosta D, Castro-Costa E, Jackson J, Shaji KS (2009) Packages
of Care for Dementia in Low- and Middle-Income Countries. PLoS Med 6(11):
e1000176. doi:10.1371/journal.pmed.1000176
Academic Editor: Vikram Patel, London School of Hygiene and Tropical
Medicine, United Kingdom
Published November 3, 2009
Copyright:  2009 Prince et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: No specific funding was received for this piece.
Competing Interests: DA is Chair of Alzheimer’s Disease International. JJ is the
ex-Chief Executive of Alzheimer Scotland.
Abbreviations: BPSD, behavioural and psychological symptoms; ChEI, cholin-
esterase inhibitor; HIC, high income country; LMIC, low- and middle-income
country; RCT, randomised controlled trial.
* E-mail: m.prince@iop.kcl.ac.uk
Provenance: Commissioned; externally peer reviewed.
PLoS Medicine | www.plosmedicine.org 1 November 2009 | Volume 6 | Issue 11 | e1000176health care workers could, with a few hours training, identify dementia
in the community with a positive predictive value of 66% [16,17].
Population screening for dementia is not considered cost-effective even
in HICs [18]. Selective screening can be accomplished by cognitive
testing or by informant report of cognitive and functional decline.
The Mini-Mental State Examination [19] is widely used in HICs,
and adapted versions have been developed for use in many LMICs
[20–22]. However, this assessment takes 10 min to administer and is
prone to educational and cultural bias [23,24]. A systematic review
of brief screening assessments identified three tests (the General Practi-
tioner Assessment of Cognition, Mini-Cog, and Memory Impairment
Screen) that took less than 5 min to administer and were considered
suitable and valid for routine use in general practice [25]; none of these
tests has been validated in LMICs.
Dementia diagnosis requires cognitive testing, clinical interview,
informant interview, and physical examination. The 10/66
Dementia Research Group’s culture- and education-fair diagnostic
protocol is validated in many LMICs [26,27], but requires
adaptation for clinical use. Practice guidelines in HICs [18]
advocate a routine ‘‘dementia screen’’ to exclude treatable causes,
which includes haematology, biochemistry, thyroid function tests,
vitamin B12 and folate levels. The feasibility and cost-effectiveness
of this approach needs to be tested in LMICs.
Finally, a recent systematic review based on evidence collected
in HICs identified good practice for disclosing dementia diagnosis.
This practice should include: preparation; integrating family
members; exploring the patient’s perspective; disclosing the
diagnosis; responding to patient reactions; focusing on quality of
life and wellbeing; planning for the future; and communicating
effectively [28]. The person assessed should be asked if they, and/
or others wish to be told the diagnosis. If so, they should be given
information about the signs, symptoms, and course of dementia,
available treatments, care and support services.
Physical Assessment
To avoid missing underlying conditions, a physical assessment is
recommended before specific treatments for BPSD are initiated [29],
and should be a regular part of care for all patients. BPSD may
sometimes be caused by pain, constipation, and urinary tract infection,
although such associations are not always observed [30]. Pain is
common and poorly controlled in severe dementia [31]. Hearing and
visual impairment impede communication and exacerbate disorienta-
tion, and deafness predicts rapid cognitive decline [32,33]. Visual and
auditory impairment can be associated with hallucinations and
delusions [34,35]. Studies indicate that all these impairments are
overrepresented in people with cognitive impairment [36–38].
There have been very few trials of the effects of physical
assessments and interventions on the course of dementia. In a
randomised controlled trial (RCT), pain assessment among nursing
home residents with dementia was associated with increased
analgesic use, reduced pain, and improvements in staff morale
[39]. Uncontrolled studies show that audiological assessment is
feasible, that hearing aids can be beneficial [40], and that referral to
an optician to improve visual acuity may reduce visual hallucinosis
[34]. Nutrition is often impaired because of apathy, aversive feeding
Box 1. International Classification of Diseases
10 Criteria for Dementia and Commonly
Occurring Features
Diagnostic criteria (ICD-10 Diagnostic Guidelines)
‘‘The primary requirement for diagnosis is evidence of a
decline in both memory and thinking which is sufficient to
impair personal activities of daily living. The impairment of
memory typically affects the registration, storage, and retrieval
of new information, but previously learned and familiar
material may also be lost, particularly in the later stages.
There is also impairment of thinking and of reasoning capacity,
and a reduction in the flow of ideas. The processing of
incoming information is impaired, in that the individual finds it
increasingly difficult to attend to more than one stimulus at a
time, such as taking part in a conversation with several
persons, and to shift the focus of attention from one topic to
another. If dementia is the sole diagnosis, evidence of clear
consciousness is required. The above symptoms and
impairments should have been evident for at least 6 months
for a confident clinical diagnosis of dementia to be made’’ [1].
The diagnostic criteria do not convey a sense of the typical
progression of the disorder:
A person with mild dementia has noticed deterioration
in their memory for recent events. For example, they may
forget that their daughter had visited the previous day.
They also find it difficult to concentrate, think flexibly, plan,
and take decisions. They are likely to feel bewildered,
anxious and sad. They may become angry and defensive
when others point out errors.
A person with moderate dementia has severe memory
problems. Only early memories are retained. Recent events are
not remembered, or rapidly forgotten. They may not know the
day, date or time of day. They often do not know where they
are. They cannot communicate clearly, having problems
finding the right word and using the wrong words. They
may hear voices or see things that are not there, and can
develop false beliefs, for example that children are entering
their house and stealing things. They are likely to be anxious,
sad, bewildered, and can become agitated or aggressive.
A person with severe dementia has complete memory
loss. They may no longer recognise their close family. They
have severe speech difficulties or are unable to communi-
cate. They may be apathetic and totally inactive, but at
times can be agitated and verbally and physically aggres-
sive. They cannot coordinate their physical movements;
may have lost the ability to walk and feed themselves and
have difficulty swallowing. They are likely to be incontinent.
Summary Points
N Two-thirds of people with dementia live in low- and middle-
income countries (LMICs), where there are few services
available and levels of awareness and help-seeking are low.
N After early diagnosis, the principal goals for manage-
ment of dementia are optimising physical health,
cognition, activity, and wellbeing; detecting and treating
behavioural and psychological symptoms (BPSD); and
providing information and long-term support to carers.
N Routine packages of continuing care should comprise
diagnosis coupled with information, regular needs
assessments, physical health checks, and carer support,
and where necessary carer training, respite care, and
assessment and treatment of BPSD.
N Care can be delivered by trained primary care teams
working in a collaborative care framework. Continuing care
with practice-based care coordination, and community
outreach are essential components of this model.
N Efficient care delivery in LMICs involves integrating dementia
care with that of other chronic diseases and community-
support programs for the elderly and disabled.
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sustain, nutritional supplementation improved nutrition among
nursing home residents [41]; nutritional education for carers had
the same effect in the community [42]. A ‘‘vascular care’’ secondary
preventive intervention for people with dementia and cerebrovas-
cular disease (part of current good practice guidelines [18]) that
addressed hypercholesterolemia, hypertension, smoking, obesity,
exercise,andmicronutrientdeficiencyhadnoimpacton subsequent
cognition, disability, or institutionalisation [43].
Psychological Treatments
A well-conducted RCT of cognitive stimulation (reality orienta-
tion, games, discussions based on information processing rather
than knowledge) conducted in the United Kingdom as a group
intervention [44], and a small pilot trial from Brazil [45], suggest
that cognitive benefits from this intervention are similar to those for
cholinesterase inhibitors (ChEIs). More specific cognitive training
produced no benefits [46]. Cognitive rehabilitation, an individual-
ised therapy designed to enhance residual cognitive skills and cope
withdeficits, showed promise in uncontrolled case series undertaken
in HICs [46]. A meta-analysis of four trials of reminiscence therapy
(the discussion of past activities, events, and experiences) [47]
provides evidence for short-term improvement in cognition, mood,
and carer strain, but the quality of these trials was poor.
Pharmacological Treatments
Targets for pharmacological treatment include cognitive
impairment, behavioural symptoms (agitation and aggression),
and psychological symptoms (depression, anxiety, and psychosis).
Table 1. The evidence in support of dementia management.
Outcome Intervention Evidence from HICs Evidence from LMICs
Identifying
dementia
Validity of screening
measures
Systematic review of screening properties of brief cognitive test
and informant screening assessments, validated in general practice
or community settings [25]
Adapted versions of the Mini Mental State
ExaminationinIndia,China,Brazil[20–22];Community
Screening Instrument for Dementia (CSID) [102,103]
Assessing needs Camberwell
Assessment of Needs
in the Elderly (CANE)
Development, reliability, and validity in UK, US, and Sweden [104] Feasibility and reliability in Brazil, community
study [94]
Cognitive
impairment
ChEIs Meta-analyses of RCTs of donepezil, rivastigmine, and galantamine
in Alzheimer’s disease [48–51]; Meta-analysis of RCTs of donepezil,
rivastigmine, and galantamine for vascular cognitive impairment [57]
Small RCT of donepezil in Brazil [52]; Open label
trials of galantamine in Brazil [53] and China [54]
Memantine Meta-analysis of RCTs of memantine [56]; Meta-analysis of RCTs of
memantine for vascular cognitive impairment [57]
—
Nonpharmacological
interventions
Meta-analysis of RCTs of reminiscence therapy [47]; RCT of cognitive
stimulation [44]; Meta-analyses of RCTs of cognitive training and
rehabilitation [46]
a
Small pilot trial of cognitive stimulation in Brazil
[45]
Behavioural
symptoms
Conventional
antipsychotic drugs
Meta-analysis of RCTs of haloperidol [60] —
Atypical
(second-generation)
antipsychotic drugs
M e t a - a n a l y s e so fR C T so fr i s p e r i d o n e ,o l a n z a p i n e ,q u e t i a p i n e ,a n d
aripiprazole for the treatment of BPSD, aggression, and agitation
[61,62]
—
ChEIs Meta-analysis of RCTs of ChEIs for the treatment of BPSD [51] —
Memantine Meta-analyses of RCTs of memantine in severe dementia [56,58] —
SSRI
antidepressants
Small RCT of citalopram for the treatment of agitation [73];
Meta-analysis of RCTs of trazodone [72]a; RCT of sertraline [74]a
—
Anticonvulsants Two small RCTs of carbamezepine [76,77] —
Environmental/
sensory
interventions
Meta-analysis of RCTs of massage and light touch [81]; Meta-analysis
of the efficacy of aroma therapy [105]; Meta-analysis of RCTs of
Snoezelen (multisensory stimulation) [79]
a; Meta-analysis of RCTs
of light therapy [78]
a
—
Depression Antidepressant
pharmacotherapy
Meta-analysis of RCTs of antidepressants to treat depression in
dementia [70]
a
—
Carer interventions Meta-analyses of RCTs and nonrandomised trials of carer
interventions for improving mood in the care recipient [84,86]
—
Psychosis Atypical
antipsychotic drugs
Meta-analyses of RCTs of atypical antipsychotic drugs for the
treatment of psychosis in Alzheimer’s disease [61,62]
—
Carer strain,
subjective
wellbeing, and
psychological
morbidity
Carer interventions Meta-analyses of controlled studies (including nonrandomised trials)
of carer interventions in general [86] and the specific effects of
psychoeducational, interventions, CBT, counselling, and respite care
[84]; Meta-analysis of RCTs of respite care [87]
a
Two small RCTs of a carer education and training
intervention in Goa, India [89] and in Moscow, Russia
[90]
Institutionalisation Carer intervention Meta-analysis of controlled studies (including nonrandomised trials) of
carer interventions in preventing or delaying institutionalisation [84,88]
—
aThe evidence from these trials and meta-analyses is inconclusive, usually because of a combination of the following factors: small trials; small number of trials; flawed
methodology (see text for details).
SSRI, selective serotonin reuptake inhibitor.
doi:10.1371/journal.pmed.1000176.t001
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(donepezil [48], rivastigmine [49], and galantamine [50]). The use
of each of these drugs is associated with modest and comparable
improvements in cognitive function, global clinical state, and
activities of daily living [51]. The evidence base for ChEIs from
LMICs is limited to one small RCT of donepezil in Brazil [52] and
open-label trials of galantamine in Brazil [53] and China [54].
The efficacy of this class of drugs in severe dementia is unclear,
although useful cognitive benefits were identified for galantamine
[55]. A fourth drug for the treatment of cognitive impairment,
memantine, has a different mode of action, and is well tolerated,
but evidence for its efficacy is limited to people with moderate to
severe dementia [56]. ChEIs and memantine are less efficacious in
vascular dementia than in other forms of dementia [57]. Their
efficacy for the treatment of disturbed behaviour is not established;
manufacturer-sponsored licensing trials [51] and post hoc analyses
[58] indicate small improvements that have not been confirmed in
independent trials [59] and meta-analyses [56].
Meta-analyses of RCTs of haloperidol [60] and atypical
antipsychotic drugs for the treatment of agitation [61] and BPSD
[62] indicate small treatment effects, most evident for aggression
[62,63]. Atypical antipsychotic drugs have also been widely
prescribed for psychosis in dementia, but a meta-analysis of their
efficacy indicated that only aripiprazole had a statistically and
clinically significant effect [62]. Use of these drugs in dementia is
associated with an increased risk of death and cerebrovascular
adverse events [62,64–68].
The benefits of antidepressant treatment in older people are
clear [69], but a meta-analysis of their efficacy in people with
dementia was inconclusive [70]. Only two small trials were
included in this meta-analysis, one of which suggested a benefit of
sertraline for some depression outcomes [71]. Antidepressants
have also been proposed for the treatment of BPSD. A meta-
analysis of two small RCTs of trazodone was inconclusive [72].
Citalopram showed efficacy over placebo for the treatment of
agitation in one small RCT [73], while sertraline showed no
benefit on any primary behavioural endpoint [74].
A systematic review of trials of anticonvulsants to treat BPSD
found sodium valproate to be ineffective [75]. Carbamezepine
may be more promising with large benefits noted for global clinical
outcomes and agitation in one small parallel group trial [76] and
more marginal effects in a small pilot trial [77].
Sensory Therapy
Various sensory therapies have been proposed as treatments for
BPSD but the evidence base for this approach is small and limited
by the poor quality of the trials. Current evidence does not support
the use of bright light therapy [78] or multisensory stimulation
[79]. One small RCT of aromatherapy suggested considerable
benefit across a range of behavioural outcomes [80]. Another
small but well-conducted trial suggested that hand massage may be
effective in reducing agitation [81,82]. More evidence is required
to confirm efficacy, exclude the possibility of harm, and define the
optimal content and mode of administration of sensory therapies
in both HICs and LMICs, where the approach is untested.
Carer-Focused Interventions
A large literature attests to the benefits of carer interventions in
dementia [83]. These include: psychoeducational interventions,
often including carer training; psychological therapies such as
cognitive behavioural therapy (CBT) and counselling; carer
support; and respite care. Many interventions combine several of
these elements. There are several systematic reviews and meta-
analyses of these interventions [84–88]; all of the constituent trials
in these studies were conducted in HICs, and many were
nonrandomised [84]. Outcomes studied include carer strain,
depression, and subjective wellbeing; behaviour disturbance and
mood in the care recipient; and institutionalisation. Most carer-
focused interventions seemed to reduce carer strain and
depression, CBT having the largest impact on depression [84].
Psychoeducational interventions required the active participation
of the carer (for example, in role-playing activities) to be effective
[84]. Carer support increased carer wellbeing but no other
outcomes [84]. For respite care, three methodologically flawed
RCTs showed no benefit on any outcome [87]. However,
nonrandomised studies suggest that respite care significantly
reduces carer strain and psychological morbidity [84]. Interven-
tions targeting the carer may also have small but significant
beneficial effects upon the behaviour of the person with dementia
[84]. A systematic review of ten RCTs indicated a 40% reduction
in the pooled odds of institutionalisation [88]; the effective
interventions were structured, intensive, and multicomponent,
offering a choice of services and supports [84,88]. Two small trials
in LMICs of a brief carer education and training intervention, one
from India [89] and one from Russia [90] indicated much larger
treatment effects on carer psychological morbidity [89] and strain
[90] than typically seen for such interventions in HICs.
Delivery of Effective Interventions
The mechanisms by which effective dementia care treatments
may be delivered in LMIC settings are summarized in Table 2.
Interventions to Increase Demand for Services
Alzheimer’s Disease International has identified raising aware-
ness of dementia among the public, carers, and health workers as a
global priority, with an increase in demands for services as one of
the intended benefits [91]. Awareness can be raised in several
ways. The establishment of a critical mass of informed carers can
assist awareness-raising, provide advice and support to families,
and work with Alzheimer’s disease associations to lobby for more
services that better meet the needs of carers. Community solidarity
can also effect change through support for health and social
welfare policies based on equity and justice. Aware communities
can provide support and reduce stigma and exclusion. Policy-
makers can be held to account by media campaigns and advocacy
from committed NGOs. In HICs, awareness is growing rapidly,
with the media playing an important role [92]. Media in LMICs
can be receptive to these stories, but efforts are required to alert
them to the importance of ageing and dementia, and to build their
capacity to report the problem [92].
Intergenerational solidarity can be promoted through aware-
ness-raising among children and young adults. In many LMICs,
many people with dementia live in multigenerational households
with young children, and children or children-in-law are the most
frequent carers for people with dementia [10], and the most likely
to initiate help-seeking. Finally, in LMICs the provision of
disability pensions and carer benefits will inevitably increase
requests for diagnostic assessment. Importantly, however, efforts to
increase awareness must be accompanied by health system and
service reform, so that help-seeking is met with a supply of better-
prepared, more responsive services.
Interventions to Improve the Capacity of Health Care Teams
Primary health care services in LMICs often fail older people
because they are clinic-based and preoccupied with simple
curative interventions [13–15]. A paradigm shift is needed to
encompass continuing care and support as part of a wider chronic
PLoS Medicine | www.plosmedicine.org 4 November 2009 | Volume 6 | Issue 11 | e1000176disease strategy. Given the frailty of many older people with
dementia, there is also a need for outreach to assess and manage
patients in their own homes. The World Health Organization
(WHO) Innovative Care for Chronic Conditions framework [93]
proposes that the delivery of care for chronic conditions can be
improved through a dialogue to build commitment for change,
Table 2. Delivering dementia care treatments.
Step How By Whom In What Settings
Increasing demand Improve awareness among general population, carers,
health professionals
Alzheimer’s associations, other chronic disease
NGOs, health professionals, media, government
Schools
Combat stigma — Public arena
Provide age-appropriate, accessible services — General practice,
primary care
Provide disability pensions for people with dementia,
and carer benefits
— Professional
education
institutions
Increasing capacity of
health care teams
Training of community, primary, and secondary
general health care providers (diagnosis, needs
assessment, health checks, care package)
Medical, nursing, and rural health schools Primary care
Paradigm shift to chronic, continuing care Dementia specialist clinicians Secondary general
health care
Support and supervision from specialists — —
Increasing recognition Community-based case finding [16,17] Community health care workers Community
Selective screening in primary and secondary care [25] Nonspecialist clinicians Primary care
Specialist centers Dementia specialist clinicians Secondary general
health care
— — Memory clinics
Adapting treatments to
increase acceptability or
reduce cost
Integrate dementia prevention and care into new
chronic disease programs [93]
Community health care workers to deliver carer
interventions and act as care coordinators [100]
Community
Provide outreach (home-based assessment and care) Nonspecialist clinicians to diagnose dementia,
optimize physical health, assess needs, and plan
community support
Primary care
Integrate long-term care and support interventions
into programs for all dependent elderly
Carers and other volunteers Secondary general
health care
Ensure carer interventions are culturally appropriate [89] — —
Provide group interventions for carers [83] — —
Develop and use cheaper generic versions of ChEIs and
SSRI antidepressants, where available and indicated
——
Practice-based
programs to deliver
effective treatments
Train primary care staff as dementia and elder care case
managers [100]
Primary care case managers Primary care
Establish collaborative care [100] with involvement of
specialist teams
Primary care clinicians —
— Primary care health care workers —
— Dementia care specialist —
Community-based
programs to deliver
effective treatments
Train carers and establish and support groups Community health care workers Community
Home outreach and individualized intervention Peer (carer-to-carer) support and training —
Respite at home and homecare Community volunteers —
Addressing impact of the
disorder on other health/
social outcomes
Carer interventions Government social welfare agencies Community
Carer benefits Community health care workers Primary care
Respite care and homecare programs Case managers —
Disability benefits and social pensions for older people [106] — —
Regular physical health checks — —
Nutritional interventions — —
SSRI, selective serotonin reuptake inhibitor.
doi:10.1371/journal.pmed.1000176.t002
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approach, care centered on patients and families, support for
patients in the community, and an emphasis on prevention.
Dementia care should be an essential component of such chronic
disease care strategies. Training of nonspecialist health profes-
sionals should focus on case-finding and on conveying the
diagnosis to patients and carers together with information and
support, needs assessment, and carer training and support.
Training can be service-based as well as through changes to the
medical and nursing school, public health, and rural health
curricula. Medical and community care services should be planned
and coordinated to respond to the increasing need for support as
the disease progresses.
Interventions to Improve Recognition
The focus here should be first upon case-finding by community
health workers [16,17], and then on selective screening coupled
with simplified ‘‘quasi-diagnostic’’ algorithms and needs assess-
ments [94] by nonspecialist clinicians. More research is needed to
identify the most feasible and valid methods.
Interventions to Increase the Acceptability and Reduce
the Costs of Treatments
At present, the costs of ChEIs are reimbursed in some Latin
American countries and Chinese provinces, generic ChEIs are
available in India, and Huperzine A, a cheap plant extract with
similar properties to ChEIs is used in China [95]. In what is a very
active and promising field for drug development [96], any new
agent with radical disease-modifying properties will be very
expensive, which raises important ethical and practical challenges
to securing equitable access. An international effort leveraged by
grass roots advocacy (similar to that mounted for antiretroviral
treatment for HIV) might be required to secure affordable supplies
for people with dementia living in LMICs. More positively, costs of
primary care and community interventions can be minimised
through task-shifting to nonspecialist and paraprofessional staff
and integration with more broadly based chronic disease [93],
disability, and elder care programmes [97,98]. In India a
community-based palliative care program has been successfully
extended to include dementia care [99].
Practice-Based Programs to Deliver Effective Treatment
Most LMICs have insufficient specialists to provide national
frontline dementia services. Diagnosis and needs assessment can
be conducted in primary care, although increased specialist input
to help with advice, inpatient or outpatient review of refractory
BPSD, and respite care would be desirable. Routine physical
reviews within practice-based programs are important but
research is needed into the cost-effectiveness of haematological
and biochemical screening, and the feasibility and effectiveness of
interventions to improve hearing, vision, nutrition, and conti-
nence. A commitment to continuing care is essential, with regular
review and physical health and needs assessments. Practice-based
case managers can coordinate this process; this collaborative care
model reduced BPSD and carer strain in an RCT in the US [100].
Community-Based Programs to Deliver Effective
Treatments
Carer-support programs can be delivered individually or in
groups by community health workers or by experienced carers.
Carer strain, whether or not associated with BPSD, should trigger
more intensive intervention that includes psychological assessment
and depression treatment for the carer [101], respite, and carer
education and training. Such interventions could be incorporated
into horizontally constructed community-based programs that
address the generic needs of frail, dependent older people and
their carers, whether these needs arise from cognitive, mental, or
physical disorders.
Packages of Care for Dementia in LMICs
On the basis of our review, we have proposed a package of care
for LMICs that considers the availability of resources for the
detection, diagnosis, and treatment of dementia in this setting. In
Table 3, the main features of this package are compared with
typical recommendations for well-resourced HIC settings. To
improve care for dementia in LMICs, we propose that the basic
package of care should focus upon diagnosis coupled with
information, regular needs assessments, physical health checks,
and carer support. This package should be extended to include
carer training, respite care, and assessment and treatment of BPSD
Table 3. Packages of care for dementia.
Low Resourced Settings High Resourced Settings [107]
Public information campaigns Public information campaigns
Community case-finding; Primary care diagnosis and needs assessment National network of specialist memory services, for diagnosis and as entry point into care
pathway
Provision of information for people with dementia and carers Provision of information for people with dementia and carers
Continuity of support, coordinated by primary care case manager Continuity of support, coordinated by specialist case manager
Regular case review with reassessment of needs; Specialist consultation
and referral where available
Integrated and continuing health and social care by multidisciplinary specialist care team
Cautious use of antipsychotic drugs and other experimental treatments
for BPSD, not as first line treatment, and preferably initiated and
reviewed by specialists
Cautious use of antipsychotic drugs and other experimental treatments for BPSD, not as
first line treatment, and initiated and reviewed by specialists
Anticholinesterase drug treatment for cognitive impairment is unlikely
to be seen as a cost-effective priority within most resource-poor systems
Anticholinesterase drugs for memory impairment, when considered cost-effective, with
specialist initiation and review
Carer-support groups; Individualised community-based carer
interventions and support
Comprehensive carer’s strategy for people with dementia; Community personal support
Promote access to general health care Effective care in general hospitals, intermediate care and care homes. Effective end of life
care
doi:10.1371/journal.pmed.1000176.t003
PLoS Medicine | www.plosmedicine.org 6 November 2009 | Volume 6 | Issue 11 | e1000176where possible. We suggest that that care can best be delivered by
trained primary care teams, with a paradigm shift towards chronic
continuing care and community outreach. Practice-based care
coordinators are an essential component of this package, ideally
working within a collaborative-care framework. Finally, we note
that care delivery will be more efficient when integrated with that
of other chronic diseases, and more broadly based community-
support programs for the elderly and disabled.
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